MCM
RPTP

Moore Capital Management’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Moore Capital Management’s Portfolio RPTP Stock Details RPTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-100,000
Closed -$605K – 425
2015
Q3 		$605K Buy
+100,000
New +$1.23M 0.03% 247

Other funds holding RPTP

CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Moore Capital Management's RPTP Position: Q4 2015 in Review

Moore Capital Management sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2015, closing a stake of 100,000 shares — an estimated $605K sold.

Moore Capital Management first reported a position in RPTP in Q3 2015 and held it in 1 quarter. The position peaked at $605K in Q3 2015. 108 funds tracked by Wall St. Rank hold RPTP as of Q4 2015.

  • Moore Capital Management reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2015 after selling out during the quarter.
  • Moore Capital Management sold 100,000 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2015, an estimated $605K.
  • Moore Capital Management first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q3 2015 and held it in 1 quarter.
  • Moore Capital Management's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $605K in Q3 2015.
  • 108 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2015.

Based on Moore Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.